J. Molner has entered into an agreement with the US Centers for Medicaid and Medicare Services (CMS)Tallinn, 2024-03-04 11:00 CET --
In a significant move that underscores its commitment to accessible healthcare, J. Molner AS (MOLNR), a generic pharmaceutical company listed on Nasdaq Tallinn First North, is proud to announce it has entered into an agreement with the US Centers for Medicaid and Medicare Services (CMS). This will see J. Molner providing rebates to all states with a Medicaid State Plan, enhancing the affordability of its high-quality generic medications for millions of Americans.
The Medicaid Drug Rebate Program is a pivotal component of the US healthcare system, requiring drug manufacturers to offer rebates on outpatient drugs to state Medicaid programs. In exchange, states provide coverage for these drugs to their Medicaid enrollees. This program is vital for ensuring that essential medications are accessible to the low-income population, a principle that aligns with J. Molner's mission to deliver affordable healthcare solutions.
For J. Molner, participation in the Medicaid rebate program represents a strategic milestone. As a generic pharmaceutical company, this agreement not only amplifies our impact on public health by making our medications more accessible to a wider audience but also solidifies our commitment to supporting the US healthcare system. By offering rebates, we are ensuring that our products are both affordable and available to the populations who need them the most.
Implementation of J. Molner's participation across all US states is underway, with each state adopting the Molner rebate program in phases. The process is expected to be fully complete by the end of March 2024, marking a significant step forward in our efforts to support healthcare affordability and access in the United States.
“This agreement with CMS is a reflection of J. Molner’s dedication to healthcare accessibility and our ongoing efforts to make a meaningful difference in the lives of patients across the US,” said Jason Grenfell-Gardner, Founder of J. Molner AS. “By participating in the Medicaid rebate program, we are not only adhering to our commitment to affordability but also laying down a pathway for the future, where high-quality healthcare is within reach for everyone.”
J. Molner AS remains dedicated to its mission of providing affordable, high-quality generic medications and looks forward to the positive impact this agreement will have on healthcare access in the United States.
For more information about J. Molner AS and its initiatives, please visit www.jmolner.com.
Jason Grenfell-Gardner
J. Molner AS
Management Board member
+372 536 00 346
jason@jmolner.com
|